Sysmex (OTCMKTS:SSMXY) Shares Gap Up – What’s Next?

Sysmex Corporation ADR (OTCMKTS:SSMXY) shares gapped up prior to trading on Friday . The stock had previously closed at $9.43, but opened at $10.01. Sysmex shares last traded at $10.01, with a volume of 511 shares changing hands.

Analyst Upgrades and Downgrades

Separately, Zacks Research downgraded shares of Sysmex from a “hold” rating to a “strong sell” rating in a research report on Tuesday, July 14th. One investment analyst has rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Sysmex has a consensus rating of “Hold”.

Sysmex Stock Up 5.3%

The company has a debt-to-equity ratio of 0.12, a current ratio of 3.26 and a quick ratio of 2.46. The firm’s 50-day moving average price is $8.96 and its 200 day moving average price is $9.07. The firm has a market cap of $6.29 billion, a P/E ratio of 26.29 and a beta of 1.07.

Sysmex (OTCMKTS:SSMXY) last announced its quarterly earnings data on Thursday, May 14th. The company reported $0.02 earnings per share for the quarter, missing the consensus estimate of $0.04 by ($0.02). Sysmex had a net margin of 7.13% and a return on equity of 7.23%. The firm had revenue of $877.92 million during the quarter, compared to the consensus estimate of $862.45 million. Sysmex has set its FY 2026 guidance at 0.370-0.370 EPS. On average, equities research analysts expect that Sysmex Corporation ADR will post 0.42 earnings per share for the current fiscal year.

About Sysmex

Sysmex Corporation (OTCMKTS: SSMXY) is a Japan‐based provider of in vitro diagnostic solutions, specializing in haematology, coagulation, urinalysis and immunochemistry systems. Headquartered in Kobe, the company designs and manufactures a comprehensive portfolio of automated analyzers, reagents and software to support clinical laboratories, hospitals and research institutions. Sysmex’s product lineup also includes digital pathology platforms and data management tools that integrate workflow automation and advanced analytics.

The company’s core offerings center on haematology analyzers such as the XN-Series, which deliver high‐speed, high‐volume testing for blood cell counts and differential analysis.